CHRONIC MYELOGENOUS LEUKEMIA: A REVIEW AND UPDATE OF CURRENT AND FUTURE THERAPY
Journal Title: International Journal of Pharmacy and Pharmaceutical Sciences - Year 2016, Vol 8, Issue 7
Abstract
Leukemia is a cancer of marrow and blood, which is a clonal myeloproliferative disease, characterized by the presence of oncogenic Philadelphia chromosome, formed by a reciprocal translocation between chromosomes 9 and 22, resulting in the novel chimeric oncoprotein BCR/ABL. Chronic leukemia typically progresses slowly and permits the growth of greater numbers of more developed cells. If the cell change takes place in a type of marrow cell that normally goes on to form red blood cells, some kinds of white blood cells and platelets, the leukemia is called “myeloid. Therapy for chronic myeloid leukemia depends on the stage of CML patient. After diagnosis and confirmation of CML positive patient, treatment available for patients includes imatinib that is an early diagnosed treatment for CML but after some duration of time, it may lead to resistance to imatinib treatment. Dasatinib, nilotinib, bosutinib & ponatinib can be used for the treatment of CML as secondary treatments. Ponatinib is also found effective against T315i mutation patients. Omacetaxine mepesuccinate can be given with a mechanism of action independent of tyrosine kinase inhibition. Clinical trial for development of advanced therapy, which includes combination therapy and newer developed a treatment against CML are going on. It is required to develop better drug therapy, which will not cause genetical mutation and drug resistant. It is also required to find out thecause of resistance and what are the possible ways by which better therapy for CML is possible.Keywords: Philadelphia (Ph) chromosome, chronic myeloid leukemia, Imatinib, Tyrosine Kinase Inhibitor (TKI), Haematological Response (HR), Cytogenetic Response (CR), Molecular Responses (MR), Reverse Transcriptase Polymerase Chain Reaction (RTPCR), BCR-ABL gene, T315I mutation, Imatinib-Resistance
Authors and Affiliations
Ankit Ashokkumar Darji, Praful D Bharadia
Keywords
Related Articles
- EP ID EP576206
- DOI -
- Views 72
- Downloads 0
INFLUENCE OF PEPTIDE P34 ON GENE EXPRESSION OF LISTERIA MONOCYTOGENES AND LISTERIA SEELEGERI
Objective: Investigate the influence of the antimicrobial peptides P34 and nisin on the expression of genes associated with components of the cell surface of Listeria monocytogenes and Listeria seeligeri.Methods: Antimic...
DESIGN AND EVALUATION OF MODIFIED CHITOSAN BASED IN SITU GEL FOR OCULAR DRUG DELIVERY
Objective: The object of the present study was to formulate and evaluate in-situ gel of modified chitosan by using temperature triggered method to improve bioavailability.Methods: Modified chitosan-based moxifloxacin HCl...
QUICK/SLOW BIPHASIC RELEASE OF A POORLY WATER SOLUBLE ANTIDIABETIC DRUG FROM BI-LAYER TABLETS
Objective: The objective of the present work is to develop a bi-layer tablet consisting of an Immediate Pulse Release [IPR] layer and a sustained release [SR] layer that can produce a distinct biphasic release having two...
ER, PR, HER2/NEU STATUS AND RELATION TO CLINICOPATHOLOGICAL FACTORS IN BREAST CARCINOMA
Objective: The role of hormone receptors as a prognostic and therapeutic tool in breast cancer is widely accepted. The aim of this study was to the analysis of steroid receptor status in breast cancer with clinic patholo...
DRUG UTILIZATION PATTERN IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE INPATIENTS AT A TERTIARY CARE HOSPITAL
Objective: Drug utilization studies provide useful insights into the current prescribing practices. In view of this, the present study was designed to establish the drug utilization pattern in hospitalized chronic obstru...